Marije E Weidema1, Ingrid M E Desar2, Melissa H S Hillebrandt-Roeffen2, Anke E M van Erp2, Mikio Masuzawa3, Uta E Flucke4, Winette T A van der Graaf5, Yvonne M H Versleijen-Jonkers2. 1. Department of Medical Oncology, Radboud University Medical Center, Internal Postal Code 452, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands. Marije.Weidema@radboudumc.nl. 2. Department of Medical Oncology, Radboud University Medical Center, Internal Postal Code 452, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands. 3. Department of Regulation Biochemistry, Kitasato University School of Allied Sciences, Sagamihara, Japan. 4. Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands. 5. Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Abstract
PURPOSE: Angiosarcoma (AS) is a rare vasoformative sarcoma, with poor overall survival and a high need for novel treatment options. Clinically, AS consists of different subtypes, including AS related to previous UV exposure (UV AS) which could indicate susceptibility to DNA damage repair inhibition. We, therefore, investigated the presence of biomarkers PARP1 (poly(ADP-ribose)polymerase-1) and Schlafen-11 (SLFN11) in UV AS. Based on experiences in other sarcomas, we examined (combination) treatment of PARP inhibitor (PARPi) olaparib and temozolomide (TMZ) in UV AS cell lines. METHODS: Previously collected UV AS (n = 47) and non-UV AS (n = 96) patient samples and two UV AS cell lines (MO-LAS and AS-M) were immunohistochemically assessed for PARP1 and SLFN11 expression. Both cell lines were treated with single agents PARPi olaparib and TMZ, and the combination treatment. Next, cell viability and treatment synergy were analyzed. In addition, effects on apoptosis and DNA damage were examined. RESULTS: In 46/47 UV AS samples (98%), PARP1 expression was present. SLFN11 was expressed in 80% (37/46) of cases. Olaparib and TMZ combination treatment was synergistic in both cell lines, with significantly increased apoptosis compared to single agent treatment. Furthermore, a significant increase in DNA damage marker γH2AX was present in both cell lines after combination therapy. CONCLUSION: We showed combination treatment of olaparib with TMZ was synergistic in UV AS cell lines. Expression of PARP1 and SLFN11 was present in the majority of UV AS tumor samples. Together, these results suggest combination treatment of olaparib and TMZ is a potential novel AS subtype-specific treatment option for UV AS patients.
PURPOSE:Angiosarcoma (AS) is a rare vasoformative sarcoma, with poor overall survival and a high need for novel treatment options. Clinically, AS consists of different subtypes, including AS related to previous UV exposure (UV AS) which could indicate susceptibility to DNA damage repair inhibition. We, therefore, investigated the presence of biomarkers PARP1 (poly(ADP-ribose)polymerase-1) and Schlafen-11 (SLFN11) in UV AS. Based on experiences in other sarcomas, we examined (combination) treatment of PARP inhibitor (PARPi) olaparib and temozolomide (TMZ) in UV AS cell lines. METHODS: Previously collected UV AS (n = 47) and non-UV AS (n = 96) patient samples and two UV AS cell lines (MO-LAS and AS-M) were immunohistochemically assessed for PARP1 and SLFN11 expression. Both cell lines were treated with single agents PARPi olaparib and TMZ, and the combination treatment. Next, cell viability and treatment synergy were analyzed. In addition, effects on apoptosis and DNA damage were examined. RESULTS: In 46/47 UV AS samples (98%), PARP1 expression was present. SLFN11 was expressed in 80% (37/46) of cases. Olaparib and TMZ combination treatment was synergistic in both cell lines, with significantly increased apoptosis compared to single agent treatment. Furthermore, a significant increase in DNA damage marker γH2AX was present in both cell lines after combination therapy. CONCLUSION: We showed combination treatment of olaparib with TMZ was synergistic in UV AS cell lines. Expression of PARP1 and SLFN11 was present in the majority of UV AS tumor samples. Together, these results suggest combination treatment of olaparib and TMZ is a potential novel AS subtype-specific treatment option for UV AS patients.
Authors: M Agulnik; J L Yarber; S H Okuno; M von Mehren; B D Jovanovic; B E Brockstein; A M Evens; R S Benjamin Journal: Ann Oncol Date: 2012-08-21 Impact factor: 32.976
Authors: Sara M Federico; Alberto S Pappo; Natasha Sahr; April Sykes; Olivia Campagne; Clinton F Stewart; Michael R Clay; Armita Bahrami; Mary B McCarville; Sue C Kaste; Victor M Santana; Sara Helmig; Jessica Gartrell; Anang Shelat; Rachel C Brennan; Dana Hawkins; Kimberly Godwin; Michael W Bishop; Wayne L Furman; Elizabeth Stewart Journal: Eur J Cancer Date: 2020-08-11 Impact factor: 9.162
Authors: Jordi Barretina; Giordano Caponigro; Nicolas Stransky; Kavitha Venkatesan; Adam A Margolin; Sungjoon Kim; Christopher J Wilson; Joseph Lehár; Gregory V Kryukov; Dmitriy Sonkin; Anupama Reddy; Manway Liu; Lauren Murray; Michael F Berger; John E Monahan; Paula Morais; Jodi Meltzer; Adam Korejwa; Judit Jané-Valbuena; Felipa A Mapa; Joseph Thibault; Eva Bric-Furlong; Pichai Raman; Aaron Shipway; Ingo H Engels; Jill Cheng; Guoying K Yu; Jianjun Yu; Peter Aspesi; Melanie de Silva; Kalpana Jagtap; Michael D Jones; Li Wang; Charles Hatton; Emanuele Palescandolo; Supriya Gupta; Scott Mahan; Carrie Sougnez; Robert C Onofrio; Ted Liefeld; Laura MacConaill; Wendy Winckler; Michael Reich; Nanxin Li; Jill P Mesirov; Stacey B Gabriel; Gad Getz; Kristin Ardlie; Vivien Chan; Vic E Myer; Barbara L Weber; Jeff Porter; Markus Warmuth; Peter Finan; Jennifer L Harris; Matthew Meyerson; Todd R Golub; Michael P Morrissey; William R Sellers; Robert Schlegel; Levi A Garraway Journal: Nature Date: 2012-03-28 Impact factor: 49.962
Authors: Edwin Choy; James E Butrynski; David C Harmon; Jeffrey A Morgan; Suzanne George; Andrew J Wagner; David D'Adamo; Gregory M Cote; Yael Flamand; Cyril H Benes; Daniel A Haber; Jose M Baselga; George D Demetri Journal: BMC Cancer Date: 2014-11-05 Impact factor: 4.430
Authors: Vaia Florou; Andrew E Rosenberg; Eric Wieder; Krishna V Komanduri; Despina Kolonias; Mohamed Uduman; John C Castle; Jennifer S Buell; Jonathan C Trent; Breelyn A Wilky Journal: J Immunother Cancer Date: 2019-08-08 Impact factor: 13.751
Authors: M Casparie; A T M G Tiebosch; G Burger; H Blauwgeers; A van de Pol; J H J M van Krieken; G A Meijer Journal: Cell Oncol Date: 2007 Impact factor: 6.730